A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
about
Targeted therapies in sarcomas: challenging the challengePazopanib in the management of advanced soft tissue sarcomasOsteosarcoma: Current Treatment and a Collaborative Pathway to SuccessIncidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysisAdvances in the management of osteosarcomaReview of Osteosarcoma and Current ManagementReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersAddition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case SeriesExploring targeted therapy of osteosarcoma using proteomics dataOff-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.A case report of apatinib in treating osteosarcoma with pulmonary metastases.Osteosarcoma Overview.Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.Treatment pathway of bone sarcoma in children, adolescents, and young adultsAnimal models in osteosarcoma.Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisRPN2 Gene Confers Osteosarcoma Cell Malignant Phenotypes and Determines Clinical Prognosis.Emerging therapeutic targets for synovial sarcoma.Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastasesGemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bonePazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.New systemic therapy options for advanced sarcomas.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewPromise and pitfalls of quantitative imaging in oncology clinical trials.Identification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxibPhase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.Future directions in the treatment of osteosarcoma.Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patientsA review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?Alternative formulations of sorafenib for use in children.Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma.Histology-specific therapy for advanced soft tissue sarcoma and benign connective tissue tumors.Safety and feasibility of targeted agent combinations in solid tumours.Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.
P2860
Q21285014-488AC028-BE67-4956-9CDF-30F0ECC95030Q26746205-64F6B24B-F0C4-44CC-B961-A7895720FD72Q26797555-B6D2D35F-A17F-4056-8F2D-EAE6D198C183Q27003304-96B5A136-0C66-4EED-9B3A-72B45A9743FBQ28067644-B3C2989E-54E6-48CE-88D1-CF513AEE8870Q28077590-C3655B5D-423A-420C-871F-6594C45812C6Q28082793-79E88838-E667-4C57-9644-B81E22152297Q28550228-0B14B4AC-492C-4B33-A476-5E995794D96EQ28817274-92BEAEF7-22AD-454E-A950-DBDBB44D981EQ31018689-A70039B5-6094-448E-ABEF-F4E9E4520D39Q33408668-A73A01BA-9A14-4284-8164-2BEF16AD067CQ33428775-9CAC35F1-6BEE-4020-9FD1-FFCA30DEC0C5Q33597266-DF07C4D2-E206-49DD-8B61-712410C505F7Q33725511-DFF97388-76CF-42AA-9187-006A95714D76Q33805555-6D9B7BAE-D98A-4204-9DFB-25D316D7D80FQ33835657-F0A6D512-5F55-49BC-918D-ADC1AD8CF7ECQ33917772-E6EFE16F-2930-4DFE-9831-9AAB8EAE7E3BQ34272887-5F7145B0-5CD5-4A36-802D-36A1E3BC66B9Q34436450-901CEAED-38CE-43F4-A821-08CF0DDBD1A9Q34660607-48250CC7-88E4-4781-85C4-298A3E06475EQ35987375-E784408A-8E6F-45E4-85B8-4FB6C1326BECQ35995283-1E1316D7-FDA6-4593-9BA9-270F1D370F21Q36097737-EA832826-C65D-4D53-807B-D5B6FB380D3EQ36166394-4DE3D80F-2963-4F32-AD40-0CD60F70E262Q36270115-77683866-D5AA-42C9-899E-0E8DDCE9A2A2Q36303765-4C4E9387-0BF0-4DFB-9B8A-296FFC303E17Q36316518-6328EDD2-4460-460C-8157-9D2530925074Q36356334-B4DC5C26-02A9-4F40-A1C0-8745CCBBFBE9Q36511158-A38D4869-8015-47D2-845F-3C1DF2C83A12Q36600800-1CEE2E06-AADD-4452-A27C-E5A6A2D3679EQ36846801-8E5DAEC6-B5AC-4CDA-8872-960ABB686D33Q36888962-FBB10389-0BC2-4F02-B993-11F78533502DQ36996436-C383E025-C2BD-46ED-9E8F-B6EE5D6BB205Q37239947-AA95477E-FFE4-4D79-BC4B-A252D385966FQ37481150-868120E1-540F-4159-A791-DE7DFAED548EQ37944599-EBA6FF83-3591-45D8-B26F-F878BBE20769Q38011606-08B29404-10DB-4604-9564-AEA63B442F33Q38077440-4BB95FE0-D526-442D-867D-1BDD22E2B391Q38103397-D7AFFB28-560F-4C6A-8561-C1D28A95C210Q38120777-2A1F8D22-1FD0-4F5C-AF91-FA290254845B
P2860
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phase II trial of sorafenib ...... n Italian Sarcoma Group study.
@ast
A phase II trial of sorafenib ...... n Italian Sarcoma Group study.
@en
A phase II trial of sorafenib ...... n Italian Sarcoma Group study.
@nl
type
label
A phase II trial of sorafenib ...... n Italian Sarcoma Group study.
@ast
A phase II trial of sorafenib ...... n Italian Sarcoma Group study.
@en
A phase II trial of sorafenib ...... n Italian Sarcoma Group study.
@nl
prefLabel
A phase II trial of sorafenib ...... n Italian Sarcoma Group study.
@ast
A phase II trial of sorafenib ...... n Italian Sarcoma Group study.
@en
A phase II trial of sorafenib ...... n Italian Sarcoma Group study.
@nl
P2093
P2860
P356
P1433
P1476
A phase II trial of sorafenib ...... n Italian Sarcoma Group study.
@en
P2093
E Palmerini
G Grignani
L D'Ambrosio
M Aglietta
P G Casali
S D Asaftei
P2860
P304
P356
10.1093/ANNONC/MDR151
P577
2011-04-28T00:00:00Z